Browsing Tag
Alzheimer’s Disease
56 posts
PRX012 Alzheimer’s trial: Can Prothena rebound from birtamimab setback?
After a major clinical failure, Prothena shifts focus to Alzheimer’s drug PRX012. Will this next trial restore investor confidence?
Sanofi to acquire Vigil Neuroscience for $470m to advance TREM2-targeting Alzheimer’s therapy
Sanofi to acquire Vigil Neuroscience for $470M, aiming to add VG-3927, a TREM2-based Alzheimer’s drug, to its neurology pipeline.
Longeveron 2024 revenue jumps 237%, eyes FDA approval for Lomecel-B
Longeveron Inc., a biotechnology company specializing in regenerative medicine, has reported significant financial progress alongside major advancements in…
CHMP backs Lecanemab again for early Alzheimer’s as EC reviews approval
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has reaffirmed its positive opinion on…
C2N Diagnostics bags UK MHRA approval for PrecivityAD2 blood test, advancing Alzheimer’s diagnosis
C2N Diagnostics, LLC, a leader in advanced diagnostic solutions for neurodegenerative diseases, has obtained medical device certification from…
Neuphoria Therapeutics secures milestone payment from Merck as Alzheimer’s clinical trial advances
Neuphoria Therapeutics Inc. (Nasdaq: NEUP), a late-stage biotechnology company focused on developing treatments for neuropsychiatric disorders, has announced…
Mental stimulation may reduce Alzheimer’s risk, study suggests
As people age, it is common to experience subtle changes in memory and cognitive function. Forgetting familiar names,…
C2N’s PrecivityAD2 blood test improves Alzheimer’s diagnosis and clinical decision-making, study finds
A new study has demonstrated that healthcare providers who used the PrecivityAD2 blood biomarker test, developed by C2N…
FDA approves Leqembi maintenance dosing for early Alzheimer’s treatment
The U.S. Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi (lecanemab-irmb), an…
InMed Pharmaceuticals’ INM-901 shows breakthrough potential in Alzheimer’s disease treatment
In a significant development in Alzheimer’s disease research, InMed Pharmaceuticals Inc., a biotechnology company specialising in the development…